NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether GSK and certain of its officers and/or directors have ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=128401&wire=4GSK in ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=127862&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATION ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.So what: If you purchased GSK ADRs during the Class Per ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press around changes that the new Trump Administration will be brining.. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.Description                        GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical ...

Core Insights - GSK plc is a healthcare company focused on developing, manufacturing, and commercializing general and specialty medicines, as well as vaccines [2] - The company offers a wide range of products for various diseases, including HIV, respiratory issues, cancer, and more, along with over-the-counter products [2] - GSK's vaccine portfolio addresses multiple diseases, including hepatitis, diphtheria, and measles [2] Technology and Innovation - The report provides insights into GSK's digital transformation strategies, innovation programs, and technology initiatives [3][6] - Key areas of focus include technology themes, objectives, and benefits of various technology initiatives [6] - The report details GSK's estimated ICT budgets and major ICT contracts, providing a comprehensive overview of its tech operations [6] Strategic Initiatives - GSK's technology initiatives encompass partnerships, product launches, and acquisitions [6] - The company has established accelerators, incubators, and innovation programs to enhance its digital transformation [6] - Insights into GSK's tech strategies and innovation initiatives are included, highlighting the company's commitment to advancing its technological capabilities [6]

SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, 2022.  GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating A ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Rec ...

5 February 2025 FY 2024 Results Conference call and webcast for investors and analysts gsk.com Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project' ...

Key TakeawaysGSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs.The British drugs giant said it expects 2031 revenue to be more than 40 billion pounds.GSK's fourth-quarter core earnings per share and revenue also beat estimates. GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a  stock ...